Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

about

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

Item

http://www.wikidata.org/entity/Q49843589

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@en

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@nl

type

Item

label

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@en

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@nl

prefLabel

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@en

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@nl

P1476

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

@en

P2093

Anthony Lucci

http://www.w3.org/2001/XMLSchema#string

Ko Un Park

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

A gene-expression signature as a predictor of survival in breast cancer

The MINDACT trial: the first prospective clinical validation of a genomic tool

Individualization of therapy using Mammaprint: from development to the MINDACT Trial

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

P2888

s10434-017-6254-z

P304

512-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-017-6254-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Oluwadamilola M Fayanju

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092823116

http://www.w3.org/2001/XMLSchema#string

P698

29159748

http://www.w3.org/2001/XMLSchema#string

P932

5790421

http://www.w3.org/2001/XMLSchema#string